Dr. José González-Costello, Coordinator of the Heart Failure Unit at Bellvitge University Hospital's Cardiology Service, spearheads the revision of heart transplantation distribution criteria in Spain for 2023. Published in the Revista Española de Cardiología, the article has received approval from key entities, including the Spanish Heart Failure Association-Spanish Society of Cardiology (SEC-Heart Failure Association), the Spanish National Transplant Organisation (ONT), and the Spanish Society of Cardiovascular and Endovascular Surgery (SECCE). Notably, other professionals from Bellvitge University Hospital (HUB) involved in the review include Dr Eva Oliver, from the Intensive Care Unit (ICU) and transplant coordinator, Dr José Carlos Sánchez Salado, specialist in the Cardiology Service, as well as Dr Nicolás Manito, former director of the Transplant Programme until his retirement.

A framework agreement has been approved between the Barcelona Chamber of Commerce and the Southern Metropolitan Territorial Management of the Catalan Health Institute (GTMS-ICS) to promote innovation, academic collaboration, research, and knowledge transfer in the fields of health and integrated care, with a particular focus on the sustainability of the healthcare system.

In October, the Arrhythmia Unit of the Cardiology Service at the Bellvitge University Hospital expanded its service offerings by incorporating an innovative treatment modality for cardiac arrhythmias. This groundbreaking approach is expected to revolutionize the field of interventional cardiac electrophysiology in the coming years.

The Col·legi Oficial de Metges de Barcelona (Barcelona Medical Association) has announced the recipients of the annual Professional Excellence Awards, which will be presented on November 27. Among this year's award winners are five doctors from Bellvitge University Hospital and an additional five from the South Metropolitan Primary Care

The new drug that eliminates antibodies that bind to gram-negative bacteria, making the latter resistant to the natural immune system

Bellvitge University Hospital (HUB) has been recognised as a reference centre in Spain for destination therapy using Left Ventricular Assist Devices (LVADs), marking a significant advance in the treatment of patients suffering from advanced heart failure. This prestigious designation grants HUB the opportunity to participate in an upcoming LVAD monitoring study for destination therapy. The study is being coordinated by the Galician Agency for Knowledge Management in Health (ACIS) and is scheduled to commence in the coming weeks.